* Dennis Orgill, M.D., Ph.D., Associate Professor at Harvard Medical
School, Associate Chief of Plastic Surgery and Principal Investigator
of the Wound Healing and Tissue Engineering Laboratory at Brigham and
About the Provant Wound Therapy System
Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology
company focused on developing and marketing noninvasive regenerative
medicine products. Regenesis developed, patented, and now markets the
Provant Wound Therapy System. Our customers include health care facilities
and providers that serve patients with wounds being treated by acute care
hospitals, long- term acute care hospitals, skilled nursing facilities,
rehabilitation centers, home health care agencies, and wound care clinics.
Regenesis Biomedical, Inc.
Media: Scott Robey, VP Marketing email@example.com
Clinicians: Rick Isenberg, MD, VP Clinical Affairs
Investors: Virginia Rybski, Acting President
|SOURCE Regenesis Biomedical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved